Aberrant methylation of tumor suppressor genes in patients with refractory anemia with ring sideroblasts

Leuk Res. 2011 Apr;35(4):479-83. doi: 10.1016/j.leukres.2010.08.012. Epub 2010 Sep 22.

Abstract

This study evaluates the incidence and prognostic impact of aberrant methylation of 25 tumor suppressor genes in 40 patients with RARS, a MDS subtype, by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay. Methylation of at least one gene was detected in 18 patients (45%). The genes methylated were CDKN2B (20%), RASSF1 (18%), RARB (10%), CDH13 (7.5%) and FHIT (5%). Patients with at least one methylated gene had a significantly shorter OS than patients without methylated genes. Aberrant methylation is a frequent event in patients with RARS as in patients with high-risk MDS appears to confer a worse prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acid Anhydride Hydrolases / genetics
  • Adult
  • Aged
  • Aged, 80 and over
  • Anemia, Refractory / genetics*
  • Anemia, Sideroblastic / genetics*
  • Cyclin-Dependent Kinase Inhibitor p15 / genetics
  • DNA Methylation*
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Proteins / genetics
  • Polymerase Chain Reaction
  • Prognosis
  • Receptors, Retinoic Acid / genetics
  • Tumor Suppressor Proteins / genetics*

Substances

  • CDKN2B protein, human
  • Cyclin-Dependent Kinase Inhibitor p15
  • Neoplasm Proteins
  • RASSF1 protein, human
  • Receptors, Retinoic Acid
  • Tumor Suppressor Proteins
  • fragile histidine triad protein
  • retinoic acid receptor beta
  • Acid Anhydride Hydrolases